Effects of topical gluco-oligosaccharide and collagen tripeptide F in the treatment of sensitive atopic skin.
Sensitive skin is a dermatological problem of increasing incidence in western countries and is sometimes associated with atopic condition and bacterial sovrainfection. The purpose of this study is to evaluate in a double blind, randomized, placebo controlled trial the efficacy of gluco-oligosaccharide and collagen tripeptide F in controlling the signs and symptoms of sensitive atopic skin. Forty female subjects (age, 30-59 years) affected by non-lesional atopic sensitive skin entered the study. Skin sensitivity was determined by a dermatologist on the basis of medical history, stinging test, dermatological examination and a questionnaire. A treatment with the test products (active and placebo) was carried out for 4 weeks. Measurements and clinical evaluation were carried out at baseline and at the end of the study. The following objective parameters investigated were bacterial count, skin pH and colour, transepidermal water loss (TEWL), stratum corneum hydration, skin roughness and mechanical properties. Clinical assessment included also a scoring system for dryness, desquamation, irritation, erythema and papules. Significant differences were found in the active treated group when compared with the placebo and in particular for instrumental parameters of roughness (P < 0.02), volume (P < 0.01), TEWL (P < 0.02), erythema (P < 0.0006) and clinical parameters of dryness, desquamation and irritation (P < 0.001). Moisturization levels and skin colour improved significantly in both the active and placebo groups. In conclusion, the study shows that the modulation of bacterial proliferation and normalization of skin barrier properties and stratum corneum moisturization can improve the symptoms of sensitive skin.
Berardesca
E
E
San Gallicano Dermatological Institute, IRCCS, Rome, Italy. berardesca@berardesca.it
Abril
E
E
Serio
M
M
Cameli
N
N
D000287:Administration, Topical; D000328:Adult; D024042:Collagen Type I / Q000008:administration & dosage*; D015169:Colony Count, Microbial; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008875:Middle Aged; D009844:Oligosaccharides / Q000008:administration & dosage*; D010446:Peptide Fragments / Q000008:administration & dosage*; D013211:Staphylococcus aureus / Q000254:growth & development; D013499:Surface Properties / Q000187:drug effects; D014870:Water Loss, Insensible / Q000187:drug effects
D024042:Collagen Type I; D009844:Oligosaccharides; D010446:Peptide Fragments